DAPTOMYCIN AS ADJUNCTIVE TREATMENT FOR EXPERIMENTAL INFECTION BY Acinetobacter baumannii WITH RESISTANCE TO COLISTIN

The emergence of Acinetobacter baumannii with resistance to colistin (ABRC) led to investigation if daptomycin can be used as adjunctive to colistin for these isolates. One ABRC carbapenemase-producing bloodstream isolate was studied; minimum inhibitory concentrations of imipenem was>512 μg/ml, of daptomycin>512 μg/ml and of colistin 8 μg/ml. First, a “humanized” model of pharmacokinetics of daptomycin and colistin was developed in 18 C57Bl6 male mice. Then, 112 mice were infected by the intraperitoneal injection of the ABRC isolate and randomly assigned into four groups of once daily treatment for se ven days; A: controls treated with saline; B treated with 20mg/kg of colistin; C: treated with 50mg/kg of daptomycin; and D; treated with both agents.

Source: International Journal of Antimicrobial Agents - November 1, 2018 Category: Drugs & Pharmacology Authors: Garyfallia Poulakou, Georgios Renieris, Labros Sabrakos, Olympia Zarkotou, Katherine Themeli-Digalaki, Efstathia Perivolioti, Eleni Kraniotaki, Evangelos J. Giamarellos-Bourboulis, Nikolaos Zavras Source Type: research